

ITOG Business Meeting Agenda
Thursday, May 12, 2022
4:30-6:00 PM (EST)

Call to Order – Gregory Randolph, MD, President, Mabel Ryder, MD, Secretary, Dwight Vicks, CFO

Organizational Activity – 5/2021 – 5/2022

1a. Clinical Trials – Pending BH Review

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Accrual Status: Accruing at MDACC, Open to accrual Feb 2021
Accrual Status: Accruing
Principal Investigator: Mark Zafereo, MD Anderson Cancer Center
Principle Investigator Email: Mzafereo@mdanderson.org

OSU 17277: A Phase 1 Trial of concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF Mutated Anaplastic or Poorly Differentiated Thyroid Cancer

Accrual Status: Accruing
Principal Investigator: Manisha Shah, MD The Ohio State University
Principle Investigator Email: Manisha.shah@osumc.edu

NCI 10240: Phase II Study of Cabozantinib in combination with Nivolumab and Ipilimumab (CaboNivoIpil) in Patients with Radioiodine-refractory Differentiated Thyroid Cancer whose Cancer Progressed after 1 Prior VEGFR-Targeted Therapy

Accrual Status: Accruing
City of Hope Comprehensive Cancer Center, Moffitt Cancer Center, University of Kentucky Cancer Center, University of Pitts-burgh Cancer Institute, Mayo Clinic, Rochester, University of Southern California, Dana Farber, Memorial Sloan Kettering
Mayo Clinic-Florida, University of Utah, University of Kansas
Sponsors: CTEP/NCI, ITOG
Principal Investigator: Bhavana Konda, MD; The Ohio State University Coordinating organization: The Ohio State University
Principle Investigator Email: Bhavana.Konda@osumc.edu

ACCRU/ITOG 1504 Combination Immunotherapy with Multikinase Inhibitor (MKI) in Progressive, Radiiodine-refractory Differentiated Thyroid Cancers

Accrual Status: Closed to Accrual
University of Michigan, University of Colorado, Dana-Farber/Harvard CC, Ohio State University, Memorial Sloan Kettering, UCLA Medical Center, MD Anderson
Sponsors: Eisai/Merck Coordinating organization: ACCRU
Principal Investigator (PI): Bryan Haugen, MD at University of Colorado Medical Center
Principal Investigator Email: bryan.haugen@cuanschutz.edu
Co-PI: Lori Wirth, MD
Publication/Presentation Status: ASCO 2020, ESMO 2020

Selumetinib plus RAI for RAI-Avid Thyroid Cancers

Accrual Status: Closed to Accrual
Sponsor: AstraZeneca Coordinating organization: ACCRU
Principal Investigator: Alan Ho, MD at Memorial Sloan-Kettering Cancer Center
Principal Investigator Email: hoa@mskcc.org
Co-PI: Mabel Ryder, MD
Publication/Presentation Status: Pending

Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

Accrual Status: **Permanently closed (or Closed to Accrual?)**
Sponsor: Loxo-Oncology Coordinating organization: LOXO-Oncology
Leader at ITOG: Lori Wirth and ITOG protocol-specific steering committee
Leader Email: Lwirth@mgh.harvard.edu
Publication Status: Pending (N Engl J Med 2020, 383:825-835; August 27, 2020)
Presentations: ASCO Jun 2018, ATA Oct 2018

ALLIANCE A091302 Randomized Phase II Study of Sorafenib with or without Everolimus in Patients with Radioactive Iodine Re-fractory Hurthle Cell

Thyroid Cancer (PI- Dr. E. Sherman); Alliance study
Accrual Status: Permanently closed
Principal Investigator: Eric Sherman, MD Memorial-Sloan Kettering Cancer Center Principal Investigator Email: shermane@mskcc.org
Publication: Pending
Presentation: ASCO 2021

1b. Clinical Trials Incoming

Selpercatinib Doubling Time Study

Phase II thin Study-US. N=30- 50. Lilly funding. Lori and Mimi working on protocol. Mimi and Lori met with Lilly 4/18.

Dabrafenib/Trametinib versus placebo for high risk BRAF MUT thyroid cancer (Alan Ho / Alliance)

Alan submitted for Novartis review.
GWR asked for status 2-20
Transformed the concept to RAI study, now discussing with Genentech and Alliance

BRAF-HER3 Alliance Study (Eric Sherman / Boeher)

Still under review by Puma

2. ITOG New Initiatives

1. Membership Expansion

ITOG Business Meeting Agenda
Thursday, May 12, 2022
4:30-6:00 PM (EST)

- a. 27 New Members joined 2021 – 2022
 - b. New Member Jamboree 12/7/22 – 28 participants
 - c. New membership unified pathway definition, approved at retreat, to be discussed at EC and Board to be implemented 2022
2. ITOG 2.0 Committee and Task Force Membership Initiative
 - a. Board liaison, COI-DEI representatives
 - b. 11 Committees – 132 leadership and members
 - c. 7 Task Forces – 79 leadership and members
 - d. ITOG Annual Meeting Committee Townhall to debrief and discuss with general membership i, ii, and iii above
3. DEI Officer designated, Julie Ann Sosa, DEI-COI Appointees for each ITOG Committee
 4. ITOG Corporate Liaison Committee (CLC)
 - a. Eisai, Exelixis, Lilly, Bayer, Caris
 - b. Potential discussion of pipeline initiatives between corporate partners and ITOG
 5. Hurthle Cell Task Force Initiative – Bryan Haugen
 - a. HCC Summit held February 12, 2022
 - b. Prioritizing several collaborative projects, discussing funding, consideration of Hurthle Cell white paper
 6. ITOG 2.0 Retreat
 - a. Protocol Committee, Membership, International, CLC discussions
 7. Rediff Task Force – Alan Ho, Sophie Leboulleux, Lori Wirth
 - a. Rediff Summit plan
 - b. Rediff redcap database plan
 8. ITOG Outreach Program
 - a. Co-Brand Endorsed Paper “American Head and Neck Society Endocrine Surgery Section Consensus Statement on Mutational Testing in Thyroid Cancer - Multidisciplinary Surgical Oncology, Medical Oncology, Endocrinology and Pathology Consensus Statement”
 - b. ITOG/WCTC October Program
 9. ITOG Thyroid Tumor Registry/Steering Committee
 - a. Ohio State University
 - b. Colorado
 10. New Publications Committee Initiative, Lindsay Bischoff Chair
 - a. Create the Guidelines on authorship, publication types related to clinical trials, correlative studies, white papers. Outreach to sister societies: AHNS, AACE, ATA
 11. New ITOG Webinar Program
 - a. ITOG Journal Club program – Wendy Sacks, Andrew Gianoukakis, Kate Newbold, Date TBA

ITOG Business Meeting Agenda
Thursday, May 12, 2022
4:30-6:00 PM (EST)

- b. Special statistical webinar for rare cancer clinical trials – Isabelle Borget, Date TBA
- 12. ITOG Leadership Communication – Newsletter + “Two Things”
- 13. Robert Gagel Discovery Award
 - a. 2021 Herb Chen
 - b. 2022 Opens in June/July 2022

3. Committee Yearly Reports

4. Dwight Vicks Financial Committee Overview Debrief

5. 2022 Planned Initiatives

- 1. Call for 2023 Annual Meeting Hosts -- ??In-person??